Nicholas Vogelzang, MDEnriched profile
Medical Oncologist and Chairman of Medical Oncology, Comprehensive Cancer Centers of Nevada; Site Research Leader, US Oncology Research (position held until his death on September 20, 2022, deceased, not an active current role) · Comprehensive Cancer Centers of Nevada
Overview
Updated 14 Jul 2026
Nicholas J. Vogelzang is Medical Oncologist and Chairman of Medical Oncology, Comprehensive Cancer Centers of Nevada. The public record shows 1,129 publications with 69,644 citations (h-index 115), centered on Prostate Cancer Treatment and Research, Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments. It also documents an investigator role on 2 registered clinical trials.
- Most recent indexed publication: 2023 · Journal of clinical oncology
- Top research focus: Prostate Cancer Treatment and Research
- 2 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 511.
Clinical & industrytrials, payments and federal funding
Federally funded research awards.
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Sponsor: SOTIO a.s.
InvestigatorPhase 3CompletedNCT02111577 - Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Sponsor: AEterna Zentaris
InvestigatorPhase 2CompletedNCT00498966
Industry payments
21 companies reported payments to CMS in program years 2021–2022. These are public disclosures, not judgments. The latest:
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
Journal of clinical oncology
2023 - Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
Journal of clinical oncology
2022 - Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
British journal of cancer
2022
Most-cited worksby citation count (OpenAlex)
- 01Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma3,395 citations2017
- 02Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer3,348 citations2013
- 03
- 04Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer2,840 citations2015
- 05
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
- Internship
residency, and chief residency in Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗ - Board Certified
American Board of Internal Medicine, Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗ - Board Certified
American Board of Internal Medicine, Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cccnevada.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- Head of Genitourinary Oncology and Clinical Professor of Medicine
University of Nevada School of Medicine (Las Vegas and Reno), from 2004
2004verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cccnevada.com ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
Secondary affiliationsappointments beyond the home institution
- US Oncology Network / US Oncology Research
Medical Director, Research Executive Committee; Associate Chair, Developmental Therapeutics and GU Committees
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cccnevada.com ↗ - University of Nevada School of Medicine
Clinical Professor of Medicine (concurrent with CCCN practice)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cccnevada.com ↗
Media & interviewspress, podcasts and appearances
- OncLive author/video archive
multiple recorded interviews on GU oncology topics (e.g., ASCO abstract reviews, axitinib in RCC, abiraterone/enzalutamide sequencing, radium-223/ALSYMPCA trial, PROSPECT trial)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Regular contributing author
CURE Today (patient-facing oncology publication)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →curetoday.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by otherswhere others cite or feature them
- Other
onclive.com/authors/nicholas-j-vogelzang-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
- 1,431
- publications
- 164
- h-index
- 8
- trials
Toni Choueiri, MD
Brigham and Women's Hospital
- 2,494
- publications
- 152
- h-index
- 12
- trials
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
- 1,588
- publications
- 150
- h-index
- 18
- trials
Fred Saad, MD
Centre Hospitalier de l’Université de Montréal
- 1,915
- publications
- 128
- h-index
- 7
- trials